A multicenter, randomized, parallel-group, 4-week, double-blind and active comparator-controlled study to assess efficacy, safety, and tolerability of etoricoxib 60 mg once daily versus diclofenac sodium 75 mg twice daily in the treatment of chinese patients with osteoarthritis of the knee or hip

Trial Profile

A multicenter, randomized, parallel-group, 4-week, double-blind and active comparator-controlled study to assess efficacy, safety, and tolerability of etoricoxib 60 mg once daily versus diclofenac sodium 75 mg twice daily in the treatment of chinese patients with osteoarthritis of the knee or hip

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs Etoricoxib (Primary) ; Diclofenac
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 01 Oct 2008 Actual patient number (160) added as reported by ClinicalTrials.gov.
    • 01 Oct 2008 Actual end date (June 2005) added as reported by ClinicalTrials.gov.
    • 01 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top